SCHEMBL18304457

SCHEMBL18304457

CON(C)C(=O)c1cc(CO)cc(OCC(C)C)c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
XDH P47989 1/20 0.36
FAAH O00519 1/20 0.35
NR1H4 Q96RI1 3/20 0.34
ALDH1A1 P00352 2/20 0.34
HIF1A Q16665 1/20 0.34
TP53 P04637 3/20 0.34
F2 P00734 3/20 0.33
MAPT P10636 2/20 0.33
KDM4E B2RXH2 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
RXFP1 Q9HBX9 1/20 0.33
RARA P10276 1/20 0.33
RARB P10826 1/20 0.33
RARG P13631 1/20 0.33
GCK P35557 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
THRB P10828 1/20 0.33
KAT6A Q92794 1/20 0.33
MLYCD O95822 1/20 0.33
FOS P01100 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10068564 0.81 XDH (0.44) XDHNR1H4ALDH1A1MAPTKDM4E
SCHEMBL18304472 0.80 ALDH1A1 (0.44) NR1H4ALDH1A1HIF1AMAPTNPSR1
SCHEMBL18304538 0.80 NR1H4 (0.47) XDHNR1H4RARARARBRARG
SCHEMBL2714096 0.75 F2 (0.39) ALDH1A1F2KAT6AMLYCD
SCHEMBL16729520 0.71 CLK1 (0.40) MAPTKDM4EMLYCD
SCHEMBL14102043 0.70 ACHE (0.48) MAPT
SCHEMBL3567621 0.70 PTGS2 (0.39) NR1H4MAPTNPSR1RARARARB
SCHEMBL6188306 0.69 XDH (0.44) XDHFAAHALDH1A1TP53MAPT
SCHEMBL13704011 0.69 GCK (0.44) NR1H4ALDH1A1MAPTKDM4ERARA
SCHEMBL16142432 0.69 CYP4F2 (0.54) NR1H4ALDH1A1MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200115339-A1 EFFLUX-PUMP INHIBITORS AND THERAPEUTIC USES THEREOF Basilea Pharmaceutica International AG (CH) 2020-04-16 US disclosed
US-10464896-B2 Efflux-pump inhibitors and therapeutic uses thereof Basilea Pharmaceutica International AG (CH) 2019-11-05 US disclosed
US-20180179158-A1 EFFLUX-PUMP INHIBITORS AND THERAPEUTIC USES THEREOF Basilea Pharmaceutica International AG (CH) 2018-06-28 US disclosed
EP-3307725-A1 EFFLUX-PUMP INHIBITORS AND THERAPEUTIC USES THEREOF Basilea Pharmaceutica International AG (CH) 2018-04-18 EP disclosed
WO-2016198691-A1 EFFLUX-PUMP INHIBITORS AND THERAPEUTIC USES THEREOF BASILEA PHARMACEUTICA AG (CH) 2016-12-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200115339-A1 EFFLUX-PUMP INHIBITORS AND THERAPEUTIC USES THEREOF ABCB11, ABCC1, ABCC3 XDH 433/4885FAAH 2014/4885NR1H4 201/4885
US-10464896-B2 Efflux-pump inhibitors and therapeutic uses thereof ABCB11, ABCC1, ABCC3 XDH 439/4885FAAH 1981/4885NR1H4 195/4885
US-20180179158-A1 EFFLUX-PUMP INHIBITORS AND THERAPEUTIC USES THEREOF ABCB11, ABCC1, ABCC3 XDH 439/4885FAAH 1981/4885NR1H4 195/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.